healthandpharma12h
Verseon's New AI Model VersAI™ Elevates AI Accuracy in Drug Discovery with Sparse Data
Verseon International Corporation has announced that its noval AI technology, VersAI™, demonstrates superior prediction ...
healthandpharma2d
ESMO 2024: BRAFTOVI and MEKTOVI Extend Survival in Aggressive BRAF V600E-Mutant Lung Cancer
Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...
healthandpharma3d
Presented at ESMO 2024: Novartis's Kisqali Reduces Breast Cancer Recurrence Risk by 28.5%
The latest data from the Phase III NATALEE trial, presented at ESMO 2024, demonstrate that adding Kisqali (ribociclib) to standard endocrine therapy reduces the risk of breast cancer recurrence by ...
healthandpharma6d
The OVATION 2 Study and the Novel Immunotherapy IMNN-001 for Ovarian Cancer
We welcome two special guests, Dr. Stacy Lindborg, and Dr. Premal Thaker, to discuss the results of the OVATION 2 Study and ...
healthandpharma6d
European Commission Approves BRAFTOVI and MEKTOVI for BRAFV600E Mutant Lung Cancer
The European Commission has approved BRAFTOVI® and MEKTOVI® for treating advanced non-small cell lung cancer with the BRAFV600E mutation.